Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Other 1Myeloid 1Lymphoid 1

Conditions

Pre-Eclampsia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Cyclophosphamide 260fludarabine phosphate 163Methotrexate 124Rituximab 112Cytarabine 109Filgrastim 106fludarabine 92Busulfan 86Peripheral Blood Stem Cell Transplantation 83Etoposide 82Vincristine 80Radiotherapy 79Tacrolimus 73Mycophenolic Acid 72Antilymphocyte Serum 68Whole-Body Irradiation 66Melphalan 63Dexamethasone 63Cyclosporine 58Doxorubicin 51Prednisone 44Methylprednisolone 44Alemtuzumab 44Mercaptopurine 41Granulocyte Colony-Stimulating Factor 40pegaspargase 35Daunorubicin 34Clofarabine 33Thiotepa 31Asparaginase 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Furosemide × Lymphoid × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡